Silica Nanoparticles: Synthesis, Properties, Safety and Applications

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: Silica Gel Column Chromatography: How It Works and How to Choose the Silica
  • Keywords: transparent silica filler
  • Published: 2026-11-20 05:08:45
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals

How to Get a Free Silica Sample: What to Request and How to Test It

What Is Silicon Oxide? SiO vs SiO₂ Differences and Applications Explained
Although a lot of reviews have already reported on the progress of MSNs in the biomedical field (Fig. 1b ), the scope of this review supplies a more comprehensive summary over the past decades from different aspects. Throughout this review, we deliver an overview of the development history of MSNs in the biomedical field, introduce some key research advances, and summarize the diverse types of MSNs. We then summarize the nanocomposites composed of different functional inorganic factors (i.e., metal compound NPs, noble metal NPs, upconversion NPs, and metal-free NPs) with MSNs. Our review focuses on the objectives of surface functionalization of MSNs, which contain improving biocompatibility, improving targeting, and enabling precise drug delivery processes. We also highlight recent advances in MSNs-based biomedical applications, with particular stress on diverse types of targeted therapeutic plans. Lastly, we discuss the clinical translational status of MSNs and the current difficulties they face in the biomedical field.
Is Silicon Dioxide Toxic? Safety of Amorphous vs Crystalline Forms Explained
Colloidal Silicon Dioxide Excipient: Uses as a Glidant and Pharmacopeia Standards
Silica Supplier Germany: Leading Producers and Sourcing Considerations

What Is Silica? A Simple Explanation of Silica, Its Forms and Uses

What is silica (SiO₂)?

silica for beer clarification

What is the difference between fumed silica and precipitated silica?

silicon dioxide CAS 7631-86-9 Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.

What drives silica raw material prices?

quartz

Cite this article: Silica Raw Materials News. "Silica for Paint: Matting, Anti-Settling and Rheology Functions Explained ." Published 2026-11-20 05:08:45. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.